Vylor Details Pro Forma Debt Load and Reaffirms 2026 Earnings Forecast
Following its recent separation from Corteva, newly public seed specialist Vylor filed pro forma debt statements and reaffirmed its full-year 2026 operating projections.
Independent seed and genetics business Vylor Inc. filed unaudited pro forma financial statements with regulators outlining its capital structure and post-separation balance sheet. The Johnston, Iowa-based firm began regular-way trading on the New York Stock Exchange on October 1, 2026, after Corteva completed the distribution of its seed operations to stockholders.
The regulatory filing reveals that Vylor incurred substantial liabilities as part of the transaction. The company issued $1.439 billion of senior notes carrying a weighted-average interest rate of 4.15 percent. It also drew $1,500 million on a 364-day revolving credit line, which had an overall facility borrowing of $1,578 million against a $3.0 billion credit limit. Proceeds funded a $3,078 million repayment of a bilateral facility, a $761 million cash payout to New Corteva, and a $183 million transfer to satisfy an internal note. Continuing operations generated a pro forma net loss of $(480) million for the evaluated period, widening from $(391) million in the previous comparison period.
The debt disclosures arrived alongside third-quarter financial figures, in which Vylor maintained its financial outlook for 2026. Management anticipates full-year adjusted pro forma operating EBITDA of roughly $2.8 billion and adjusted pro forma operating EPS between $2.25 and $2.35. For the initial nine months of 2026, pro forma net sales rose 4 percent, aided by a 3 percent pricing and mix improvement in the Americas and higher licensing revenue. Year-to-date GAAP pro forma earnings reached $1.01 billion, or $1.50 per share, while adjusted pro forma operating EBITDA totaled $2.66 billion.
Chief Executive Officer Chuck Magro stated that executing the spinoff on schedule and under budget enables the business to pursue long-term opportunities. Long-range plans presented at an earlier investor meeting target net sales between $11.2 billion and $11.9 billion alongside approximately 30 percent operating EBITDA margins by 2029. Growth initiatives rely on a $19 billion research pipeline, including planned introductions of gene-edited corn, advanced soybean traits, and the North American rollout of hybrid wheat technology in 2027.
Capital allocation plans include a $3 billion multi-year share buyback program and a common stock payout of $0.13 per share, which investors of record by November 30, 2026, will receive on December 7, 2026. On Wall Street, 14 analysts tracked by Barchart hold a consensus Moderate Buy rating on the stock, while BNP Paribas Exane initiated coverage with a Neutral recommendation and a $75 price target.